BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1014 related articles for article (PubMed ID: 16598757)

  • 21. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
    Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
    Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma.
    Hastürk S; Kemp B; Kalapurakal SK; Kurie JM; Hong WK; Lee JS
    Cancer; 2002 Feb; 94(4):1023-31. PubMed ID: 11920472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
    González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
    Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
    Tomizawa Y; Nakajima T; Kohno T; Saito R; Yamaguchi N; Yokota J
    Cancer Res; 1998 Dec; 58(23):5478-83. PubMed ID: 9850082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
    Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
    Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
    Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
    Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
    Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
    Shi HR; Wu QH; Suo ZH; Nesland JM
    Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced HIC-1 gene expression in non-small cell lung cancer and its clinical significance.
    Hayashi M; Tokuchi Y; Hashimoto T; Hayashi S; Nishida K; Ishikawa Y; Nakagawa K; Tsuchiya S; Okumura S; Tsuchiya E
    Anticancer Res; 2001; 21(1B):535-40. PubMed ID: 11299800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
    Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
    Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.